GPP racks up $506m for fourth fund

Great Point Partners IV focuses on the lower middle market healthcare sector.

Great Point Partners has closed its fourth fund at $506 million. Great Point Partners IV focuses on the lower middle market healthcare sector.


Great Point Partners, a global health care investment firm today announced the closing of its fourth lower middle market growth buyout fund, Great Point Partners IV (GPP IV), focused on rapidly growing health care companies in the United States, Canada, and Western Europe. GPP IV, which closed on $506 million was significantly oversubscribed in four months of fundraising and closed at its hard cap.

“Great Point’s combination of both a private and public fund health care strategy enables us to have a team of approximately 30 people dedicated to generating and sharing thematic ideas across the full spectrum of the health care field. This concentration of health care focused talent working cooperatively differentiates our investment process. Since our first private equity fund launched in 2005, our private equity funds have generated a 3.9x gross multiple on realized investments as of March 31, 2022,” said Jeffrey Jay, MD, Founding Managing Director.

“Since GPP I, we have focused on lower middle market health care investments in pharmaceutical services and products, health care information technology enabled services, medical contract manufacturing, and health care services. We seek to create long-term value for our investors by maintaining a best-in-class proprietary sourcing program, partnering with great entrepreneurs, and investing in sectors with sustainable tailwinds of growth,” added Noah Rhodes, Managing Director.

“GPP IV will target majority and minority investments in profitable companies generally with $1 to $10 million of EBITDA. We are pursuing the same strategy we started two decades ago,” said Rohan Saikia, Managing Director. “We have had particular success helping companies based solely in either the US or Europe become global companies with operations in multiple countries.”

“We are grateful for our investor support, especially in a hectic and crowded fundraising environment,” added Emily St. Thomas, Head of Investor Relations and Marketing for the private equity funds and the public life sciences fund. “We continue to diversify our investor base, particularly in Europe. We manage capital for some of the most sophisticated investors in the world. It is gratifying that we are able to make a positive societal impact, as a firm that is dedicated to investing in companies that improve the health and well-being of people across the globe.”

About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III. Including GPP IV, Great Point manages $1.7B of capital in its private funds and public life sciences equity strategy. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.